Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

References

• Jones I R, Owens D R, Sarsons D L, Bloom S R. Day profiles of glucose dependent insulinotropic polypeptide (GIP) in normal subjects. Horm Metab Res 1985; 17: 660–2
   PubMedGoogle Scholar
• Jorde R, Burhol P G, Waldum H L, Schulz T B, Lygren I, Florholmen J. Diurnal variation of plasma gastric inhibitory polypeptide in man. Scand J Gastroenterol 1980; 15: 617–9
   PubMed Web of Science ®Google Scholar
• Salera M, Giacomoni P, Pironi L, Ustra C, Capelli M, Giougi A, et al. Circadian rhythm of gastric inhibitory polypeptide (GIP) in man. Metabolism 1983; 32: 21–4
   PubMed Web of Science ®Google Scholar
• Ørskov C, Holst J J, Poulsen S S, Kirkegaard P. Pancréatic and intestinal processing of proglucagon in man. Diabetologia 1987; 30: 874–81
   PubMedGoogle Scholar
• Kreymann B, Ghatei M, Williams G, Bloom S R. Glucagon‐like peptide‐1 (7–36) amide. A physiological incretin in man. Lancet 1987; 2: 1300–3
   PubMed Web of Science ®Google Scholar
• Fieseler P, Bridenbaugh S, Nustede R, Martell J, Ørskov C, Holst J J, et al. Physiological augmentation of amino‐acid induced insulin secretion by gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1), but not cholecystokinin (CCK‐8) in normal man. Am J Physiol 1995; 268: E949–55
   Google Scholar
• McIntyre N, Holdsworth C D, Turner D S. New interpretation of oral glucose tolerance. Lancet 1964; 2: 20–1
   PubMed Web of Science ®Google Scholar
• Dupre J, Ross S A, Watson D, Brown J C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826–8
   PubMed Web of Science ®Google Scholar
• Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon‐like peptide‐1 (7–36) amide infused at near‐physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912–7
   PubMed Web of Science ®Google Scholar
• Nauck M A, Büsing M, Ørskov C, Siegel E G, Talartschik J, Baartz A, et al. Preserved incretin effect of immunoreactive gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) after oral glucose in type‐1‐diabetic patients with endstage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol 1993; 30: 36–45
   PubMedGoogle Scholar
• Mentlein R, Gallwitz B, Schmidt W E. Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1 (7–36) amide, and peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829–35
   PubMedGoogle Scholar
• Deacon C F, Johnsen A H, Holst J J. Degradation of glucagon‐like peptide‐1 by human plasma in vitro yields an N‐terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952–7
   PubMed Web of Science ®Google Scholar
• Albano J D M, Ekins R P, Maritz G, Turner R C. A sensitive precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol 1972; 70: 487–509
   PubMedGoogle Scholar
• Holst J J. Evidence that enteroglucagon (II) is identical with the C‐terminal sequence (residues 33–69) of glicentin. Biochem J 1982; 207: 381–8
   PubMed Web of Science ®Google Scholar
• Holst J J, Bersani M. Assays for peptide products of somatostatin gene expression. Methods in neurosciences. Academic Press, New York 1991; 3–22
   Google Scholar
• Krarup T, Madsbad S, Moody A J, Regeur L, Faber O K, Holst J J, et al. Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics. J Clin Endocrinol Metab 1983; 56: 1306–12
   PubMedGoogle Scholar
• Moody A J, Jørgensen K D, Thim L. Structure‐function relationships in porcine GIP. Diabetologia 1981; 21: 306
   Google Scholar
• Moody A J, Krarup T, Larsen U D. Reactivity of anti‐porcine gastric inhibitory polypeptide (GIP) rabbit antiserum R65 with synthetic human and porcine GIP. Scand J Clin Lab Invest 1992; 52: 103–6
   PubMed Web of Science ®Google Scholar
• Krarup T, Holst J J, Larsen K L. Responses and molecular heterogeneity of IR‐GIP after intraduodenal glucose and fat. Am J Physiol 1985; 249: E195–200
   PubMedGoogle Scholar
• Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst J J. Production and secretion of amidated and glycine‐extended glucagon‐like peptide‐1 (GLP‐1) in man. Diabetes 1994; 43: 535–9
   PubMed Web of Science ®Google Scholar
• Holst J J. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994; 107: 1848–55
   PubMed Web of Science ®Google Scholar
• Eissele R, Göke R, Willemer S, Harthus H P, Vermeer H, Arnold R, et al. Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992; 22: 283–91
   PubMed Web of Science ®Google Scholar
• Ørskov C. Glucagon‐like peptide‐1, a new hormone of the entero‐insular axis. Diabetologia 1992; 35: 701–11
   PubMed Web of Science ®Google Scholar
• Miholic J, Ørskov C, Holst J J, Kotzerke J, Meyer H J. Emptying of the gastric substitute, glucagon‐like peptide‐1 (GLP‐1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 1991; 36: 1361–70
   PubMedGoogle Scholar
• Herrmann C, Göke R, Richter G, Fehmann H ‐C, Arnold R, Göke B. Glucagon‐like peptide‐1 and glucose‐dependent insulin‐releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117–26
   PubMed Web of Science ®Google Scholar
• Brubaker P L. Regulation of intestinal proglucagon‐derived peptide secretion by intestinal regulatory peptides. Endocrinol 1991; 128: 3175–3182
   PubMed Web of Science ®Google Scholar
• Roberge J N, Brubaker P L. Regulation of intestinal proglucagon‐derived peptide secretion by glucose‐dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993; 133: 233–40
   PubMed Web of Science ®Google Scholar
• Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh S P, Holst J J. Glucagon‐like peptide‐1 (GLP‐1) 7–36 amide and peptide YY from the L‐cell in the ileal mucosa are potent inhibitors of vagally induced gastric acid in man. Scand J Gastroenterol 1994; 29: 501–5
   PubMed Web of Science ®Google Scholar
• Nauck M A, Siemsglüss J, Ørskov C, Holst J J. Release of GLP‐1 (7–36 amide) after oral glucose in patients with upper and lower gut resections [abstract]. Gut 1995, In press
   Google Scholar
• Holst J J, Schwartz T W, Lovgreen N A, Pedersen O, Beck‐Nielsen H. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obesity 1982; 7: 529–38
   Web of Science ®Google Scholar
• Holst J J, Ørskov C. Glucagon and other proglucagon‐derived peptides. Gut peptides, J H Walsh, G J Dockray. Raven Press, New York 1994; 305–40
   Google Scholar
• Valverde I, Alarcon C, Ruiz‐Grande C, Rovira A. Plasma glucagon and glucagon‐like immunoreactivity in totally pancreatectomized humans. Diabetes secondary to pancreatopathy, A Tiengo. Excerpta Medica, Amsterdam 1988; 51–62
   Google Scholar
• Ørskov C, Jeppesen J, Madsbad S, Holst J J. Proglucagon products in plasma of non‐insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine. J Clin Invest 1991; 87: 415–23
   PubMedGoogle Scholar
• Holst J J. Degradation of glucagons. Degradation of bioactive substances: physiology and pathophysiology, J H Henriksen. CRC Press, Boca Raton, FL 1991; 167–80
   Google Scholar
• Ørskov C, Wettergren A, Holst J J. The metabolic rate and the biological effects of GLP‐1 7–36 amide and GLP‐1 7–37 in healthy volunteers are identical. Diabetes 1993; 42: 658–61
   PubMed Web of Science ®Google Scholar
• Grandt D, Sieburg B, Sievert J, Schimiczek M, Becker U, Holtmann G, et al. Is GLP‐1 (9–36) amide an endogenous antagonist at GLP‐1 receptors? [abstract]. Digestion 1994; 55: 302
   Google Scholar
• Holst J J, Bersani M, Johnsen A H, Kofod H, Hartmann B, Ørskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem 1994; 269(18)827–33
   Google Scholar
• Elliott R M, Morgan L M, Tredger J A, Deacon S, Wright J, Marks V. Glucagon‐like peptide‐1 (7–36) amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: postprandial and 24‐h secretion patterns. J Endocrinol 1993; 138: 159–66
   PubMed Web of Science ®Google Scholar
• Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 1988; 9: 122–34
   PubMed Web of Science ®Google Scholar
• Krarup T, Groop P ‐H. Physiology and pathophysiology of GIP: a review. Scand J Clin Lab Invest 1991; 51: 571–9
   PubMedGoogle Scholar
• O'Dorisio T M, Sirinek K R, Mazzaferri E L, Cataland S. Renal effects of serum gastric inhibitory polypeptide (GIP). Metabolism 1977; 26: 651–6
   PubMed Web of Science ®Google Scholar
• Sarson D L, Hayter R C, Bloom S R. The pharmacokinetics of porcine glucose‐dependent insulinotropic polypeptide (GIP) in man. Eur J Clin Invest 1982; 12: 457–61
   PubMedGoogle Scholar
• Rossowski W J, Zacharia S, Mungan Z, Ozmen V, Ertan A, Baylor L M, et al. Reduced gastric acid inhibitory effect of a pGIP (1–30) NH2 fragment with potent pancreatic amylase inhibitory activity. Regul Pept 1992; 39: 9–17
   PubMedGoogle Scholar
• Lauritsen K B, Holst J J, Moody A J. Depression of insulin release by anti‐GIP serum after oral glucose in rats. Scand J Gastroenterol 1981; 16: 417–20
   PubMed Web of Science ®Google Scholar
• Ebert R. Gut signals for islet hormone release. Eur J Clin Invest 1990; 20(Suppl 1)S20–6
   Google Scholar
• Lauritsen K B, Moody A J, Christensen K C, Jensen S L. Gastric inhibitory polypeptide (GIP) and insulin release after small‐bowel resection in man. Scand J Gastroenterol 1980; 15: 833–40
   PubMed Web of Science ®Google Scholar
• Kolligs F, Fehmann H ‐C, Göke R, Göke B. Reduction of the incretin effect in rats by the GLP‐1 receptor antagonist exendin (9–39) amide. Diabetes 1995, In press
   PubMedGoogle Scholar
• Wang Z, Wang R M, Owji A A, Smith D M, Ghatei M A, Bloom S R. Glucagon‐like peptide‐1 is a physiological incretin in rat. J Clin Invest 1995; 95: 417–22
   PubMed Web of Science ®Google Scholar